TriSalus Life Sciences announced the publication of research titled 'Intra-arterial Pressure-Enabled Drug Delivery Significantly Increases Penetration of Glass Microspheres in a Porcine Liver Tumor Model' in the peer-reviewed Journal of Vascular and Interventional Radiology. The study highlighted the superior performance of the TriNav Infusion System in delivering glass microspheres (GM) into liver tumors when compared to delivery with a traditional microcatheter in a transgenic (oncopig) model.
The research demonstrated a 117% increase in tumor penetration with lobar infusions and a 39% increase with selective infusions using the PEDD method compared to conventional delivery. These findings provide high-resolution evidence of enhanced delivery, supporting the effectiveness of the PEDD approach in overcoming challenges in cancer care.
The study also indicated that lobar PEDD delivery of GM to the tumor was statistically equivalent to conventional selective delivery (p=0.497). This suggests a potential to selectively target multiple tumors simultaneously in patients with heavy disease burdens, further validating the wide-ranging applicability of the PEDD approach.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.